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The crystal structure of the title compound, C16H16FN2O2
+I
,
was determined as part of a study of the biological activity of
isoxazolone derivatives as p38 mitogen-activated protein
kinase (MAPK) inhibitors. The X-ray crystal structure of 4-[4-
(4-ﬂuorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-3-yl]-1-
methylpyridinium iodide showed the presence of the regioi-
somer 4-[3-(4-ﬂuorophenyl)-2-methyl-5-oxo-2,5-dihydro-
isoxazol-4-yl]-1-methylpyridinium iodide. The synthesis of
the former compound was achieved by reacting 4-(4-ﬂuoro-
phenyl)-3-(4-pyridyl)isoxazol-5(2H)-one after treatment with
Et3N in dimethylformamide, with iodomethane. The unex-
pected formation of the regioisomer could be explained by a
rearrangement occurring via aziridine of the isoxazolone
compound. The regioisomers have site occupancies of
0.632 (4)/0.368 (4). The two six members rings make a
dihedral angle of 66.8 (2).
Related literature
For general background on the pharmaceutical applications of
isoxazolones, see: Laughlin et al. (2005); Clark et al. (2002);
Wang et al. (1998); Foster et al. (2000); Adams et al. (1998);
Laufer & Wagner (2002); de Laszlo et al. (1998); Laufer et al.
(2005, 2006); Revesz et al. (2000); Ohkawa et al. (2001). The
aziridine rearrangement of isoxazolones was described by








a = 10.2804 (4) A ˚
b = 20.5895 (9) A ˚
c = 7.4907 (3) A ˚
  = 96.8828 (14)
V = 1574.12 (11) A ˚ 3
Z =4
Mo K  radiation
  = 2.05 mm
1
T = 193 (2) K
0.52  0.20  0.08 mm
Data collection




Tmin = 0.415, Tmax = 0.853
27681 measured reﬂections
3897 independent reﬂections












 max = 1.60 e A ˚ 3
 min = 0.51 e A ˚ 3
Data collection: APEX2 (Bruker, 2006); cell reﬁnement: APEX2;
data reduction: APEX2; program(s) used to solve structure: SIR92
(Altomare et al., 1994); program(s) used to reﬁne structure:
SHELXL97 (Sheldrick, 1997); molecular graphics: ORTEP
(Johnson, 1968) and PLATON (Spek, 2003); software used to
prepare material for publication: SHELXL97.
The authors thank the EU-Craft Programme, Project
Macrocept (FP6), for funding.
Supplementary data and ﬁgures for this paper are available from the
IUCr electronic archives (Reference: BT2577).
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4-[4-(4-Fluorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-3-yl]-1-methylpyridinium  iodide-4-[3-
(4-fluorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-4-yl]-1-methylpyridinium iodide (0.6/0.4)
S. Margutti, D. Schollmeyer and S. Laufer
Comment
Compound (II) (Scheme 1) was prepared in the course of our study on isoxazolones derivatives bearing the typical vicinal
4-pyridyl and 4-fluorophenyl pharmacophores of MAP Kinase inhibitors. Isoxazolones are described in the literature as
inhibitors for p38 MAP Kinase (Laughlin et al., 2005; Clark et al., 2002).
The prototypical pyridinylimidazole SB 203580 is one of the best studied p38 inhibitors reported until now. Fig. 1 shows
the most important interactions between the ATP binding sites of p38 kinase and the imidazole inhibitor SB203580 (Wang
et al., 1998). The 4-fluorophenyl ring of SB203580 occupies a hydrophobic back pocket gaining selectivity. Vicinal to this
interaction site, 4-pyridinyl moiety forms a hydrogen bond from the backbone NH group of Met 109 of p38 MAP Kinase
(Fig. 1).
However, certain liver toxicities, such as increased liver size and increased cytochrome P450 induction, have been re-
ported (Foster et al., 2000; Adams et al., 1998). In light of this potential toxicity and the risks associated with developing
human drugs, a continuing need exist for potent new small molecules inhibitors of cytokine production with improved
pharmacokinetic and safety profiles.
Several research groups have undertaken studies in which the imidazole ring was replaced by other 5- or 6- membered
heterocycles (Laufer & Wagner, 2002; de Laszlo et al., 1998; Laufer et al., 2006; Revesz et al., 2000; Ohkawa et al., 2001).
Replacement of the core heterocycle representing a strategy to dissect inhibition of p38 from interferences with cytochrome
P450 (CYP450).
Accordingly, and based on the research published by Laughlin and co-authors (Laughlin et al., 2005), we plane to prepare
N-alkylated derivatives of compound (I) in order to get more accurate and comparable information about isoxazolones as
p38 MAP Kinase inhibitors in terms of biological activity.
By testing compounds (I) and (II) in the in vitro p38-alpha MAPK assay (Laufer et al., 2005), only compound (I) was
found to posses biological activity.
The loss of the biological activity of compound (II) can be attributed to the absence of hydrogen bond donor on the
pyridine ring and, consequentely, impossibility of interaction with Met109.
Experimental
For the synthesis of 2-(4-Fluoro-phenyl)-3-oxo-3-pyridin-4-yl-propionic acid ethyl ester (see scheme 1), to a suspension of
3.3 g (26.8 mmol) of isonicotinic acid in 15 ml of DMF, 7.3 g (45 mmol) of CDI were added. The reaction mixture was
stirred at 298 K for 1 h. The limpid solution was then cooled at 273 K and 5 g (27.4 mmol) of (4-Fluoro-phenyl)-acetic
acid ethyl and 1.7 g (70.8 mmol) of NaH were added. The reaction mixture was stirred at 273 K for 15 min, then thesupplementary materials
sup-2
temperature was raised to 298 K and kept under vigorous stirring for 4 h. The reaction was then poured into water/ice, the
pH adjusted to value 6 and extracted with ethylacetate. The combined organic layers were then collected, dried over Na2SO4
and concentrated under vacuum affording an oil that was chromatographed over SiO2 using acetone as eluent y ielding 75%
of 2-(4-Fluoro-phenyl)-3-oxo-3-pyridin-4-yl-propionic acid ethyl ester. For the synthesis of (I), a suspension of 5.2 g (18.1
mmol) of 2-(4-Fluoro-phenyl)-3-oxo-3-pyridin −4-yl-propionic acid ethyl ester and 1.41 g (20.27 mmol) of hydroxylamine
hydrochloride in 1.5 ml of H2O was warmed to 353 K. 8 ml of MeOH were added and the resulting solution allowed to reflux
4 h. The reaction mixture was then cooled to 298 K and stored at 277 K overnight whereupon a yellow solide precipitated,
yielding 75% of (I). For the synthesis of (II) and (III), a suspension of 620 mg (2.5 mmol) of (I) in 1 ml of DMF was
added of 0.620 ml (4.5 mmol) of Et3N and refluxed for 2 h. The reaction mixture was then cooled at 298 K, added of 0.231
ml (3.75 mmol) of iodomethane and stirred at 298 K for 2 h. The reaction mixture was then added of ethylacetate and the
resulting precipitate separated by filtration and then crystalized from MeOH yielding 54% of (II) and (III).
Refinement
Hydrogen atoms attached to carbons were placed at calculated positions with C—H = 0.95 A% (aromatic) or 0.99–1.00 Å
(sp3 C-atom). All H atoms were refined with isotropic displacement parameters (set at 1.2–1.5 times of the Ueq of the parent
atom). The regioisomers (II) and (III) have s.o.f.s of 0.632 (4)/0.368 (4). The coordinates and a.d.p.'s of the disorderd C, N
and F atoms were constrained to be equal to achieve a good convergence of the refinement procedure.
Figures
Fig. 1. Schematic drawing of important interactions between the prototypical pyridin-4-yl im-
idazole inhibitor SB 203580 and the ATP binding site of p38.
Fig. 2. Schematic drawings of 4-[4-(4-Fluoro-phenyl)-2-methyl-5-oxo-2,5-dihydro-isoxazol-
3-yl]-1-methyl- pyridinium iodide, (II), and 4-[3-(4-Fluoro-phenyl)-2-methyl-5-oxo-2,5-di-
hydro-isoxazol-3-yl]-1-methyl- pyridinium iodide, (III).
Fig. 3. ORTEP (Johnson, 1968) view of (II) and (III). Displacement ellipsoids are drawn at
the 50% probability level. H atoms are depicted as circles of arbitrary size.
Fig. 4. The formation of the title compound.supplementary materials
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4-[4-(4-Fluorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-3-yl]-1- methylpyridinium iodide– 4-[3-(4-
fluorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-4-yl]-1-methyl- pyridinium iodide (0.6/0.4)
Crystal data
C15H12FN2O2
+·I– F000 = 776
Mr = 398.17 Dx = 1.680 Mg m−3
Monoclinic, P21/c Mo Kα radiation
λ = 0.71069 Å
Hall symbol: -P 2ybc Cell parameters from 6868 reflections
a = 10.2804 (4) Å θ = 2.7–28.3º
b = 20.5895 (9) Å µ = 2.05 mm−1
c = 7.4907 (3) Å T = 193 (2) K
β = 96.8828 (14)º Block, brown




diffractometer 3369 reflections with I > 2σ(I)
Monochromator: graphite Rint = 0.126
T = 193(2) K θmax = 28.4º
CCD scan θmin = 2.0º
Absorption correction: multi-scan
(APEX2; Bruker, 2006) h = −13→13
Tmin = 0.415, Tmax = 0.853 k = −27→27
27681 measured reflections l = −9→9
3897 independent reflections
Refinement
Refinement on F2 Secondary atom site location: difference Fourier map
Least-squares matrix: full Hydrogen site location: inferred from neighbouring
sites
R[F2 > 2σ(F2)] = 0.040 H-atom parameters constrained
wR(F2) = 0.115
  w = 1/[σ2(Fo
2) + (0.0617P)2 + 2.8681P]
where P = (Fo
2 + 2Fc
2)/3
S = 1.07 (Δ/σ)max = 0.001
3897 reflections Δρmax = 1.60 e Å−3
188 parameters Δρmin = −0.51 e Å−3
Primary atom site location: structure-invariant direct
methods Extinction correction: nonesupplementary materials
sup-4
Special details
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance mat-
rix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations
between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of
cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, convention-
al R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2sigma(F2) is used only for calculat-
ing R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice
as large as those based on F, and R– factors based on ALL data will be even larger.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)
x y z Uiso*/Ueq Occ. (<1)
F1A 1.0107 (3) 0.20467 (16) 1.6192 (4) 0.0292 (4) 0.632 (4)
F1B 0.3217 (5) 0.1835 (3) 0.8219 (7) 0.0292 (4) 0.368 (4)
C1 0.9450 (4) 0.08719 (19) 0.9398 (5) 0.0327 (7)
C2 0.8322 (4) 0.07466 (19) 0.8261 (5) 0.0333 (7)
N3 0.8565 (3) 0.0373 (2) 0.6894 (5) 0.0458 (9)
O4 0.9887 (3) 0.02271 (16) 0.7079 (4) 0.0439 (7)
C5 1.0475 (4) 0.0546 (2) 0.8619 (6) 0.0384 (8)
C6 0.7766 (4) 0.0089 (2) 0.5375 (6) 0.0408 (9)
H6A 0.8320 −0.0168 0.4667 0.061*
H6B 0.7337 0.0435 0.4623 0.061*
H6C 0.7100 −0.0191 0.5806 0.061*
O7 1.1646 (3) 0.04901 (16) 0.8994 (5) 0.0489 (8)
C8 0.9607 (4) 0.12052 (18) 1.1149 (5) 0.0332 (8)
C9 0.8538 (4) 0.1315 (2) 1.2097 (6) 0.0359 (8)
H9 0.7687 0.1187 1.1584 0.043*
C10 0.8700 (4) 0.1609 (2) 1.3781 (6) 0.0399 (9)
H10 0.7969 0.1691 1.4412 0.048*
C11A 0.9937 (5) 0.1776 (2) 1.4501 (6) 0.0462 (9) 0.632 (4)
N11B 0.9937 (5) 0.1776 (2) 1.4501 (6) 0.0462 (9) 0.368 (4)
H11B 1.0046 0.1958 1.5571 0.055* 0.368 (4)
C12 1.1020 (4) 0.1672 (2) 1.3625 (6) 0.0458 (10)
H12 1.1868 0.1795 1.4162 0.055*
C13 1.0846 (4) 0.1386 (2) 1.1952 (6) 0.0413 (9)
H13 1.1586 0.1310 1.1333 0.050*
C15 0.6988 (4) 0.10094 (19) 0.8287 (5) 0.0312 (7)
C16 0.5906 (4) 0.06123 (19) 0.8311 (5) 0.0336 (7)
H16 0.6003 0.0153 0.8348 0.040*
C17 0.4681 (4) 0.0892 (2) 0.8282 (5) 0.0352 (8)
H17 0.3932 0.0623 0.8308 0.042*
N18A 0.4542 (3) 0.15364 (17) 0.8217 (4) 0.0292 (4) 0.632 (4)
H18A 0.3753 0.1705 0.8193 0.035* 0.632 (4)
C18B 0.4542 (3) 0.15364 (17) 0.8217 (4) 0.0292 (4) 0.368 (4)
C19 0.5569 (4) 0.1931 (2) 0.8188 (6) 0.0364 (8)supplementary materials
sup-5
H19 0.5441 0.2388 0.8156 0.044*
C20 0.6822 (4) 0.16808 (19) 0.8204 (5) 0.0354 (8)
H20 0.7552 0.1961 0.8160 0.042*
I1 0.47781 (2) 0.126317 (12) 0.31747 (3) 0.03385 (11)
Atomic displacement parameters (Å2)
U11 U22 U33 U12 U13 U23
F1A 0.0284 (10) 0.0371 (11) 0.0211 (9) 0.0016 (8) −0.0013 (7) −0.0038 (8)
F1B 0.0284 (10) 0.0371 (11) 0.0211 (9) 0.0016 (8) −0.0013 (7) −0.0038 (8)
C1 0.0289 (17) 0.0352 (19) 0.0353 (18) 0.0032 (14) 0.0087 (14) 0.0040 (14)
C2 0.0329 (18) 0.0339 (19) 0.0339 (18) 0.0020 (14) 0.0065 (14) 0.0026 (14)
N3 0.0312 (17) 0.061 (2) 0.045 (2) 0.0125 (16) 0.0037 (15) −0.0117 (17)
O4 0.0336 (14) 0.0525 (18) 0.0474 (17) 0.0086 (13) 0.0122 (12) −0.0064 (14)
C5 0.0325 (19) 0.038 (2) 0.045 (2) 0.0013 (16) 0.0092 (16) 0.0042 (16)
C6 0.040 (2) 0.042 (2) 0.042 (2) 0.0019 (17) 0.0108 (17) −0.0077 (17)
O7 0.0292 (14) 0.0528 (18) 0.067 (2) 0.0032 (12) 0.0151 (14) 0.0009 (16)
C8 0.0303 (18) 0.0346 (19) 0.0349 (19) −0.0006 (14) 0.0047 (15) 0.0048 (14)
C9 0.0286 (17) 0.046 (2) 0.0336 (19) 0.0007 (15) 0.0036 (15) 0.0009 (15)
C10 0.037 (2) 0.048 (2) 0.035 (2) 0.0035 (17) 0.0049 (16) −0.0002 (17)
C11A 0.055 (2) 0.043 (2) 0.039 (2) −0.0025 (18) −0.0002 (18) 0.0000 (17)
N11B 0.055 (2) 0.043 (2) 0.039 (2) −0.0025 (18) −0.0002 (18) 0.0000 (17)
C12 0.037 (2) 0.050 (3) 0.048 (2) −0.0095 (18) −0.0029 (18) 0.0029 (19)
C13 0.0297 (19) 0.048 (2) 0.047 (2) −0.0043 (16) 0.0057 (17) 0.0058 (18)
C15 0.0331 (17) 0.0352 (18) 0.0257 (16) 0.0025 (14) 0.0045 (13) −0.0009 (14)
C16 0.0372 (19) 0.0332 (18) 0.0313 (17) −0.0009 (15) 0.0079 (15) −0.0007 (14)
C17 0.0360 (19) 0.038 (2) 0.0323 (18) −0.0024 (15) 0.0063 (15) −0.0016 (14)
N18A 0.0284 (10) 0.0371 (11) 0.0211 (9) 0.0016 (8) −0.0013 (7) −0.0038 (8)
C18B 0.0284 (10) 0.0371 (11) 0.0211 (9) 0.0016 (8) −0.0013 (7) −0.0038 (8)
C19 0.0344 (18) 0.0363 (19) 0.0381 (19) 0.0028 (15) 0.0025 (15) 0.0013 (15)
C20 0.0318 (18) 0.0329 (19) 0.041 (2) −0.0005 (14) 0.0037 (15) −0.0014 (15)
I1 0.03172 (15) 0.03684 (16) 0.03268 (16) −0.00256 (9) 0.00260 (10) −0.00114 (9)
Geometric parameters (Å, °)
F1A—C11A 1.376 (5) C10—C11A 1.365 (6)
C1—C2 1.378 (5) C10—H10 0.9500
C1—C5 1.431 (5) C11A—C12 1.375 (7)
C1—C8 1.472 (5) C12—C13 1.378 (7)
C2—N3 1.328 (5) C12—H12 0.9500
C2—C15 1.477 (5) C13—H13 0.9500
N3—O4 1.383 (4) C15—C16 1.383 (5)
N3—C6 1.444 (6) C15—C20 1.393 (6)
O4—C5 1.400 (5) C16—C17 1.382 (5)
C5—O7 1.208 (5) C16—H16 0.9500
C6—H6A 0.9800 C17—N18A 1.336 (6)
C6—H6B 0.9800 C17—H17 0.9500
C6—H6C 0.9800 N18A—C19 1.334 (5)
C8—C13 1.392 (6) N18A—H18A 0.8800supplementary materials
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C8—C9 1.397 (6) C19—C20 1.386 (5)
C9—C10 1.390 (6) C19—H19 0.9500
C9—H9 0.9500 C20—H20 0.9500
C2—C1—C5 105.4 (3) C10—C11A—C12 122.8 (4)
C2—C1—C8 129.2 (3) C10—C11A—F1A 118.4 (4)
C5—C1—C8 125.1 (4) C12—C11A—F1A 118.8 (4)
N3—C2—C1 111.3 (3) C11A—C12—C13 118.5 (4)
N3—C2—C15 118.9 (3) C11A—C12—H12 120.8
C1—C2—C15 129.6 (4) C13—C12—H12 120.8
C2—N3—O4 108.8 (3) C12—C13—C8 121.3 (4)
C2—N3—C6 134.4 (4) C12—C13—H13 119.4
O4—N3—C6 116.8 (3) C8—C13—H13 119.4
N3—O4—C5 107.6 (3) C16—C15—C20 119.5 (3)
O7—C5—O4 117.8 (4) C16—C15—C2 122.2 (4)
O7—C5—C1 135.3 (4) C20—C15—C2 118.1 (3)
O4—C5—C1 106.9 (3) C17—C16—C15 119.1 (4)
N3—C6—H6A 109.5 C17—C16—H16 120.4
N3—C6—H6B 109.5 C15—C16—H16 120.4
H6A—C6—H6B 109.5 N18A—C17—C16 120.5 (4)
N3—C6—H6C 109.5 N18A—C17—H17 119.7
H6A—C6—H6C 109.5 C16—C17—H17 119.7
H6B—C6—H6C 109.5 C19—N18A—C17 121.6 (3)
C13—C8—C9 118.2 (4) C19—N18A—H18A 119.2
C13—C8—C1 120.4 (4) C17—N18A—H18A 119.2
C9—C8—C1 121.3 (4) N18A—C19—C20 120.7 (4)
C10—C9—C8 121.1 (4) N18A—C19—H19 119.6
C10—C9—H9 119.5 C20—C19—H19 119.6
C8—C9—H9 119.5 C19—C20—C15 118.5 (4)
C11A—C10—C9 118.2 (4) C19—C20—H20 120.7
C11A—C10—H10 120.9 C15—C20—H20 120.7
C9—C10—H10 120.9
C5—C1—C2—N3 0.7 (5) C1—C8—C9—C10 177.6 (4)
C8—C1—C2—N3 −173.3 (4) C8—C9—C10—C11A −1.2 (6)
C5—C1—C2—C15 −173.3 (4) C9—C10—C11A—C12 0.7 (7)
C8—C1—C2—C15 12.7 (7) C9—C10—C11A—F1A −177.8 (4)
C1—C2—N3—O4 0.6 (5) C10—C11A—C12—C13 −0.1 (7)
C15—C2—N3—O4 175.3 (3) F1A—C11A—C12—C13 178.4 (4)
C1—C2—N3—C6 178.3 (5) C11A—C12—C13—C8 0.2 (7)
C15—C2—N3—C6 −7.0 (8) C9—C8—C13—C12 −0.7 (6)
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